206 related articles for article (PubMed ID: 22394107)
1. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway.
Sartelet H; Imbriglio T; Nyalendo C; Haddad E; Annabi B; Duval M; Fetni R; Victor K; Alexendrov L; Sinnett D; Fabre M; Vassal G
Histopathology; 2012 Jun; 60(7):1144-55. PubMed ID: 22394107
[TBL] [Abstract][Full Text] [Related]
2. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
3. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
Zhong ZY; Shi BJ; Zhou H; Wang WB
J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
[TBL] [Abstract][Full Text] [Related]
4. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G; Hayes E; Lewis R; Ichi S; Mania-Farnell B; Shim K; Takao T; Allender E; Mayanil CS; Tomita T
Oncogene; 2016 Jan; 35(2):241-50. PubMed ID: 25823028
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric cancer cells.
Zhu Y; Yu J; Wang S; Lu R; Wu J; Jiang B
Oncol Rep; 2014 Dec; 32(6):2437-44. PubMed ID: 25230779
[TBL] [Abstract][Full Text] [Related]
6. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
7. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.
Takenobu H; Shimozato O; Nakamura T; Ochiai H; Yamaguchi Y; Ohira M; Nakagawara A; Kamijo T
Oncogene; 2011 Jan; 30(1):97-105. PubMed ID: 20818439
[TBL] [Abstract][Full Text] [Related]
8. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
[TBL] [Abstract][Full Text] [Related]
9. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line.
Vangipuram SD; Buck SA; Lyman WD
Tumour Biol; 2012 Dec; 33(6):2173-83. PubMed ID: 22886526
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
11. Activation of Akt predicts poor outcome in neuroblastoma.
Opel D; Poremba C; Simon T; Debatin KM; Fulda S
Cancer Res; 2007 Jan; 67(2):735-45. PubMed ID: 17234785
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
Sagulenko V; Muth D; Sagulenko E; Paffhausen T; Schwab M; Westermann F
Carcinogenesis; 2008 Oct; 29(10):1869-77. PubMed ID: 18566016
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
14. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
15. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
[TBL] [Abstract][Full Text] [Related]
16. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
Kohler JA; Rubie H; Castel V; Beiske K; Holmes K; Gambini C; Casale F; Munzer C; Erminio G; Parodi S; Navarro S; Marquez C; Peuchmaur M; Cullinane C; Brock P; Valteau-Couanet D; Garaventa A; Haupt R
Eur J Cancer; 2013 Nov; 49(17):3671-9. PubMed ID: 23907002
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma.
Tong QS; Zheng LD; Tang ST; Ruan QL; Liu Y; Li SW; Jiang GS; Cai JB
World J Pediatr; 2008 Feb; 4(1):58-62. PubMed ID: 18402255
[TBL] [Abstract][Full Text] [Related]
18. Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents.
Vangipuram SD; Wang ZJ; Lyman WD
Pediatr Blood Cancer; 2010 Mar; 54(3):361-8. PubMed ID: 19927294
[TBL] [Abstract][Full Text] [Related]
19. Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray.
Mehrazma M; Madjd Z; Kalantari E; Panahi M; Hendi A; Shariftabrizi A
Fetal Pediatr Pathol; 2013 Jun; 32(3):192-204. PubMed ID: 22830353
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
